Canada Markets closed

Mesoblast Limited (LWBA.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
2.7800-0.0600 (-2.11%)
At close: 09:35PM CEST
Full screen
Previous Close2.8400
Open2.8200
Bid0.0000 x 90000
Ask0.0000 x 90000
Day's Range2.7600 - 2.8200
52 Week Range2.1200 - 6.3000
Volume950
Avg. Volume15
Market Cap366.173M
Beta (5Y Monthly)2.36
PE Ratio (TTM)N/A
EPS (TTM)-0.7250
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.70
  • GlobeNewswire

    Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022

    At June 30, 2022, cash-on-hand was US$60.4 million with pro-forma US$105.5 million after raising gross proceeds of US$45 million via a private placement in August, 2022 Up to an additional US$40 million available from existing facilities subject to certain milestonesNet operating spend of US$65.8 million for the 12 months ended June 2022, a 35% reduction on comparative year, with continued focus on cost controlBLA resubmission for remestemcel-L in children with SR-aGVHD expected to be filed this

  • GlobeNewswire

    Mesoblast Corporate Update and Financial Results Webcast

    NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the fourth quarter and full-year ended June 30, 2022. The webcast will begin at 6.30pm EDT, Tuesday, August 30; 8.30am AEST, Wednesday, August 31, 2022. It can be accessed via: https://webcast.openbriefing.com/8875/ The archived webcast will be available on th

  • GlobeNewswire

    Jane Bell Joins Mesoblast Board

    NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Jane Bell to its Board of Directors. Ms Bell is a banking and finance lawyer with 22 years of corporate finance expertise focussing on international investment transactions in the United States, Canada, Australia and the United Kingdom, including funds management, mergers, acquisitions, and divestment